Stockwatch

Date	Sym	Type	Headline
2024-04-15 08:05	UU:ONVO	News Release200	Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
2024-01-25 08:05	UU:ONVO	News Release200	Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn ¢ € ™s and Colitis Congress
2024-01-09 08:05	UU:ONVO	News Release200	Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn ¢ € ™s and Colitis Congress
2023-12-06 08:05	UU:ONVO	News Release200	Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
2023-11-13 08:05	UU:ONVO	News Release200	CORRECTION ¢ € “ Organovo Highlights FXR314 Combination Therapy Potential and Plan
2023-11-08 08:06	UU:ONVO	News Release200	Organovo Highlights FXR314 Combination Therapy Potential and Plan
2023-09-08 12:46	UU:ONVO	News Release200	Organovo to Participate in the H.C. Wainwright Global Investment Conference
2023-08-23 08:05	UU:ONVO	News Release200	Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data